Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyajima, A.
Right arrow Articles by Hayakawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyajima, A.
Right arrow Articles by Hayakawa, M.
[Cancer Research 62, 4176-4179, August 1, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

Angiotensin II Type I Antagonist Prevents Pulmonary Metastasis of Murine Renal Cancer by Inhibiting Tumor Angiogenesis

Akira Miyajima1, Takeo Kosaka, Tomohiko Asano, Takako Asano, Kaori Seta, Toshiaki Kawai and Masamichi Hayakawa

Departments of Urology [A. M., T. K., To. A., Ta. A., K. S., M. H.] and Pathology [T. K.], National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Angiotensin II (AII) is a potent vasoconstrictor peptide from the renin-angiotensin system in the kidney. The AII type 1 receptor (AT1R) is reportedly expressed in several tumors including renal cell carcinoma, and AII is involved in tumor angiogenesis. We p.o. administered the long-acting AT1R antagonist, candesartan (10 mg/kg), to the 16 days mouse renal cancer lung metastasis model to test the preventive effects in tumor metastasis. Pulmonary metastases of renal cancer showed prominent AT1R expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules (14.9 ± 1.8; P < 0.0001; n = 12) in mice along with the inhibition of neovascularization and vascular endothelial growth factor expression, compared with control metastatic mice (123.3 ± 8.6; n = 13). Candesartan is widely used clinically, so it seems to be a reasonable therapy for patients with lung metastases of renal cell carcinoma.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
Between 20% and 30% of patients with localized RCC2 relapse after radical nephrectomy, although surgery is still the standard therapy for this tumor (1) . Immunotherapy with IFNs and interleukins has also been studied, because metastatic or relapsed RCC is refractory to adjuvant chemotherapy. However, the overall response rate achieved by immunotherapy remains ~20% (2) . The lung is the most common site of distant recurrence with lung metastases being found in 50–60% of patients (3) , but there is no known therapy that can reduce the rate of relapse. AII is a key biological peptide in the renin-angiotensin system that regulates blood pressure and renal hemodynamics. There are two major subtypes of the AII receptor, which are AT1R and AT2R. The AT1R belongs to the seven transmembrane domain superfamily, and its stimulation activates classical second messenger systems that lead to the rapid production of diacylglycerol and inositol 1, 4, 5-triphosphate as well as the activation of protein kinase C (4) . A potential role of AII in promoting tumor growth has been suspected based on its known hormonal actions in addition to its vasoconstrictor effect (5) . Lever et al. (6) reported the first clinical evidence that long-term AII blockade may have a protective effect against cancer and suggested that it could prevent carcinogenesis. There have been several reports that AII can induce neovascularization in experimental systems (7) via the AT1R (8) . The AT1R is also expressed frequently in various human tumors (9 , 10) . A recent in vitro study showed that treatment with an AT1R antagonist could inhibit the growth of a pancreatic cancer cell line, suggesting that AT1R blockade may be a possible treatment for cancer (11) . In addition to the potential superiority of AT1R antagonists over angiotensin-converting enzyme inhibitors with regard to the risk of stroke, the expectation has been raised that these AT1R antagonists may be useful in the prevention of cancer. In rats, the angiogenic action of AII on the cremaster muscle is mediated via the AT1R, whereas stimulation of the AT2R inhibits angiogenesis. Accordingly, specific AT1R blockade might be expected to inhibit carcinogenesis or angiogenesis more efficiently than blockade of both the AT1R and AT2R by an angiotensin-converting enzyme inhibitor. Candesartan was developed as a long-acting specific AT1R antagonist, and it has been used to treat patients with hypertension. We hypothesized that candesartan might be able to specifically delay tumor progression, and we administered it to a mouse renal cancer lung metastasis model to test its effect.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Experimental Lung Metastasis Model.
Inbred male BALB/c mice were inoculated with 2 x 105 Renca cells via the tail vein on day 0 and were randomly assigned to various treatment groups. Candesartan was generously provided from Takeda Chemical Industries (Osaka, Japan). Candesartan (10 mg/kg) in 0.5 g/dl carboxymethyl cellulose was administered p.o. every day from day 1. Carboxymethyl cellulose solution was administered as a control. On day 16, the mice were euthanized for evaluation of pulmonary metastases. When the lungs were harvested, the lungs were insufflated endotracheally with 15% India Black Ink solution and bleached in Fekete’s solution. Total metastatic nodules on the lung surface were counted, as described (12) . Animal treatment adhered to approved institutional guidelines.

Lung Histopathology.
Lung tissues were fixed in 10% formalin and embedded in paraffin. Paraffin sections (5 µm) were stained with hematoxylin. The general presence of tumor metastases was assessed in slides stained with hematoxylin.

TGF-ß1 Bioassay.
Whole lung tissue TGF-ß is extracted, and MLECs were used as described previously (13) . MLEC cells (104/well) were plated in 96-multiwell plates, and they were allowed to attach at 37°C in a humidified atmosphere of 5% CO2/95% O2. After 24 h, the medium was replaced with the test sample and incubated overnight at 37°C. For the bioassay, the TGF-ß1 in the conditioned medium was activated as follows. Samples were acidified to pH 1.5 with 1 N HCl (1 h at 4°C) followed by equilibration at neutral pH with 1 N NaOH. At the end of the incubation, [3H]thymidine incorporation assay was performed to determine the effect of samples on MLEC growth. A TGF-ß1 standard curve was carried out in the range of 0.01–2.0 ng/ml. All of the assays were performed in triplicate. Results are expressed as active form of pg/mg lung tissue TGF-ß.

RCC Sample.
Ten lung specimens were randomly selected from patients who had died of RCC (Table 1)Citation . There were 7 men and 3 women, with a mean (±SD) age of 56.0 ± 9.3 years. Histological type of 10 samples was all of a conventional type (clear cell).


View this table:
[in this window]
[in a new window]
  		Table 1 Patient profile and results of immunostaining for AT1R

 
Immunostaining of the AT1R, CD34, and VEGF.
Paraffin sections (5 µm) were deparaffinized, rehydrated, and washed in PBS. Endogenous peroxidase was quenched. A blocking step was included using 1% BSA (or 5% goat serum) in conjunction with avidin and biotin blocking solutions. Primary antibody (anti-AT1R polyclonal antibody; Santa Cruz Biotechnology, Santa Cruz, CA; anti-CD34 monoclonal antibody; HyCult Biotechnology, Uden, Netherlands; anti-VEGF polyclonal antibody; Neomarkers, Fremont, CA) was applied at 4°C overnight. Biotinylated secondary antibody was applied, then incubated with avidin-biotin peroxidase complex, and developed with diaminobenzedene. After washing slides, counterstaining was done with 10% hematoxylin for 1–2 min. CD34-positive neovessels were counted in 10 high-power fields (x400) by two independent investigators who operated in a blinded fashion. The intensity of VEGF staining in tumor lesions was graded on a scale of 0 to +3, with 0 indicating no detectable staining and +3 indicating the strongest staining. Immunopositivity of tumor lesions for VEGF was assessed in all of the lesions at a high power (x400) by two independent investigators operating in a blinded fashion, and mean value was determined. AT1R-positive cells in human lung metastasis were counted in 10 high power fields by two independent investigators working in a blinded fashion. Then the percentage of AT1R cells was graded into one of three categories: +1 (<35%), +2 (35–75%), or +3 (>75%).

Statistical Analysis.
All of the results were analyzed for significance by the ANOVA. P < 0.05 was considered significant. Statistical analysis was performed using Statview 5.0 software.


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
In the present study, immunostaining clearly demonstrated prominent expression of AT1R in the metastatic lung tumors of mice (Fig. 1A)Citation . We also observed that 9 of 10 patients showed AT1R expression in lung metastases (Fig. 1BCitation ; Table 1Citation ), which was consistent with our results in mice. The AT1R is expressed in various normal organs, including the blood vessels, brain, kidney, lung, liver, adrenal gland, and pituitary gland (14) . In situ hybridization of angiotensin receptor mRNA and ligand-binding assays have shown that the main AII receptor subtype in the pulmonary vessels is type 1 (15) . The present study showed that not only endothelial cells, but also tumor cells, expressed the AT1R in the lungs of mice (Fig. 1A)Citation . Goldfarb et al. (10) used autoradiography to demonstrate that tumor cells express the AT1R in human RCC tissues. It has been suggested that the cytoplasmic localization of AT1R in tumor cells may be attributable to its internalization (11) . Our findings regarding AT1R localization seem to be consistent with previous observations.



View larger version (132K):
[in this window]
[in a new window]
  		Fig. 1. A, AT1R expression in metastatic lung tumor of mouse RCC (x400). B, AT1R expression in metastatic lung tumor of human RCC (x200).

 
We found that injection of Renca cells into the tail vein induced multiple lung metastases in mice after 16 days. Mice without candesartan treatment had numerous nodules (Fig. 2A)Citation , whereas oral administration of candesartan caused a striking decrease of lung metastases (Table 2)Citation . Histopathological examination of hematoxylin-stained sections demonstrated that control mice had prominent lung tumor formation (Fig. 2B)Citation , whereas these changes were ameliorated by candesartan administration (Fig. 2C)Citation .



View larger version (102K):
[in this window]
[in a new window]
  		Fig. 2. A, mouse metastatic lung. Left side, control metastatic lung; right side, metastatic lung treated with candesartan. B, microscopic finding in the hematoxylin-stained slides of control metastatic lung (x40). C, microscopic finding in the hematoxylin-stained slides of metastatic lung treated with candesartan (x40).

 

View this table:
[in this window]
[in a new window]
  		Table 2 Results of lung metastatic nodules, TGF-ß content, CD34-positive cells, and VEGF-positive intensity (mean ± SE)

 
In the development of renal fibrosis, there is growing evidence that AII induces TGF-ß and that AII blockade reduces TGF-ß overexpression, suggesting that AII blockade may be of therapeutic value for fibrotic diseases (16) . TGF-ß has also been reported to play an important role in inducing angiogenesis and metastasis during cancer progression (17) . These results suggest that specific AII blockade may possibly prevent TGF-ß-induced cancer progression in the lungs. In our mouse model, we determined lung tissue TGF-ß levels by bioassay and showed that metastatic lungs had a significantly higher tissue TGF-ß content than normal lungs (Table 2)Citation . On the other hand, candesartan treatment significantly decreased the lung tissue TGF-ß content (Table 2)Citation , suggesting that AT1R blockade decreases tissue TGF-ß in metastatic lungs. However, the inhibition of TGF-ß by candesartan was not as marked as the decrease in metastatic lung nodules, so other factors may be involved. We also investigated the effect of AT1R blockade on neovascularization in the present mouse model. To evaluate neovascularization, immunostaining for CD34 was carried out. Lung metastases contained multiple CD34-positive neovessels (Fig. 3A)Citation . Candesartan treatment significantly decreased the CD34-positive tumor neovessels when compared with control lungs (Fig. 3BCitation ; Table 2Citation ). Investigation of tumor expression of VEGF in lungs of mice showed that control metastatic lung tumors had significantly stronger VEGF expression (Fig. 4A)Citation than tumors treated with candesartan (Fig. 4BCitation ; Table 2Citation ). This suggests that AT1R blockade may be able to prevent renal cancer progression by inhibiting angiogenesis.



View larger version (135K):
[in this window]
[in a new window]
  		Fig. 3. A, neovascularization in metastatic lung tumor lesion of mouse renal cancer (x400). B, neovascularization in metastatic lung tumor lesion of mouse renal cancer treated with candesartan (x400).

 


View larger version (107K):
[in this window]
[in a new window]
  		Fig. 4. VEGF expression in metastatic lung tumor lesion of mouse renal cancer. A, the section shown in representative of that obtained from control metastatic mice (x400). B, the section shown in representative of that obtained from metastatic mice treated with candesartan (x400).

 
Candesartan cilexetil has shown a potent and long-lasting antihypertensive effect in clinical trials (18) and in several animal models (19) . The irreversible inhibition of vasoconstriction by candesartan is the result of its tight binding to AT1R and slow dissociation from the AT1R (20) . After oral administration, candesartan was ~50 times more potent than losartan (a conventional AT1R antagonist) in rats (21) . These characteristics may be related to the higher potency and long action of candesartan demonstrated in the present study. A 4-week oral toxicity study of candesartan showed that doses of up to 300 mg/kg/day were not toxic in rats (22) and dogs (23) . In addition, a 26-week oral administration study revealed that the nontoxic dose of candesaratan was 10 mg/kg/day in rats (24) , so we chose 10 mg/kg/day for this study. Inada et al. (19) reported that 1 mg/kg of candesartan had no hypotensive effect in rats, and that even higher dose (10 and 100 mg/kg) reduced the blood pressure slightly (by ~10 mm Hg) and had no effect on the heart rate in normotensive rats. It was also demonstrated that oral administration of candesartan (10 mg/kg) for 2 weeks did not have an excessive hypotensive effect in rats (25) . However, this dose has not been studied clinically, although doses of up to 96 mg/day (~2 mg/kg/day) have been achieved clinically (26) . We also observed that 1 mg/kg of candesartan could significantly reduce metastatic lung nodules (55.4 ± 8.2; P < 0.001; n = 10) when compared with control metastatic mice. Because administration of candesartan at 1 mg/kg is clinically feasible, this inhibitory effect on tumor growth could be achievable and warrants additional investigation.

Only 40% of patients have RCC confined to the kidney at diagnosis, and unfortunately, 25–30% of the patients present with metastatic disease. If the tumor cannot be completely resected, the usual course is relentlessly progressive, and 85% of relapses occur during the first 3 years. Even if the tumor can be completely resected, 20–30% of patients suffer a relapse. Accordingly, the 5-year survival rate of patients with metastasis is <10% (1) . Identification of the factors that mediate relapse would help to predict the prognosis clinically. Although many prognostic factors for RCC have been reported, we often encounter patients who should not have relapsed based on the pathological stage or the biological behavior of the tumor. There are no clear answers and few methods of predicting relapse in these patients. Candesartan is already widely used clinically, and the present study suggested that it may prevent pulmonary metastasis of RCC. Therefore, the preventive effect of this promising agent on metastatic RCC should be determined clinically.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at National Defense Medical College, Department of Urology, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan. Phone: 81-429-95-1676; Fax: 81-429-96-5210; E-mail: akiram{at}ndmc.ac.jp Back

2 The abbreviations used are: RCC, renal cell carcinoma; AII, angiotensin II; AT1R, angiotensin II type 1 receptor; AT2R, angiotensin II type 2 receptor; TGF, transforming growth factor; MLEC, mink lung epithelial cell; VEGF, vascular endothelial growth factor. Back

Received 3/19/02. Accepted 6/ 6/02.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Couillard D. R., deVere White R. W. Surgery of renal cell carcinoma. Urol. Clin. N. Am., 20: 263-275, 1993.[Medline]
  2. Motzer R. J., Bander N. H., Nanus D. M. Renal-cell carcinoma. N. Engl. J. Med., 335: 865-875, 1996.[Free Full Text]
  3. Young R. C. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions?. N. Engl. J. Med., 338: 1305-1306, 1998.[Free Full Text]
  4. Helin K., Stoll M., Meffert S., Stroth U., Unger T. The role of angiotensin receptors in cardiovascular diseases. Ann. Med., 29: 23-29, 1997.[Medline]
  5. Achard J. M., Pruna A., Fernandez L. A., Hottelart C., Mazouz H., Rosa A., Andrejak M., Fournier A. Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?. Am. J. Hypertens., 12: 1050-1053, 1999.[Medline]
  6. Lever A. F., Hole D. J., Gillis C. R., McCallum I. R., McInnes G. T., MacKinnon P. L., Meredith P. A., Murray L. S., Reid J. L., Robertson J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet, 352: 179-184, 1998.[Medline]
  7. Le Noble F. A., Hekking J. W., Van Straaten H. W., Slaaf D. W., Struyker Boudier H. A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol., 195: 305-306, 1991.[Medline]
  8. Le Noble F. A., Schreurs N. H., van Straaten H. W., Slaaf D. W., Smits J. F., Rogg H., Struijker-Boudier H. A. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am. J. Physiol., 264: R460-R465, 1993.[Abstract/Free Full Text]
  9. Takeda H., Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am. J. Pathol., 158: 1633-1637, 2001.[Abstract/Free Full Text]
  10. Goldfarb D. A., Diz D. I., Tubbs R. R., Ferrario C. M., Novick A. C. Angiotensin II receptor subtypes in the human renal cortex and renal cell carcinoma. J. Urol., 151: 208-213, 1994.[Medline]
  11. Fujimoto Y., Sasaki T., Tsuchida A., Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett., 495: 197-200, 2001.[Medline]
  12. Asano T., Khanna A., Lagman M., Li B., Suthanthiran M. Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma. J. Urol., 157: 2396-2401, 1997.[Medline]
  13. Miyajima A., Chen J., Lawrence C., Ledbetter S., Soslow R. A., Stern J., Jha S., Pigato J., Lemer M. L., Poppas D. P., Vaughan E. D., Felsen D. Antibody to transforming growth factor-ß ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int., 58: 2301-2313, 2000.[Medline]
  14. Clauser E., Curnow K. M., Davies E., Conchon S., Teutsch B., Vianello B., Monnot C., Corvol P. Angiotensin II receptors: protein and gene structures, expression and potential pathological involvements. Eur. J. Endocrinol., 134: 403-411, 1996.[Abstract]
  15. Rakugi H., Okamura A., Kamide K., Ohishi M., Sasamura H., Morishita R., Higaki J., Ogihara T. Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors. Hypertens. Res., 20: 51-55, 1997.[Medline]
  16. Noble N. A., Border W. A. Angiotensin II in renal fibrosis: should TGF-ß rather than blood pressure be the therapeutic target?. Semin. Nephrol., 17: 455-466, 1997.[Medline]
  17. Pepper M. S. Transforming growth factor-ß: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev., 8: 21-43, 1997.[Medline]
  18. Sever P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J. Hum. Hypertens., 11 (Suppl.2): S91-S95, 1997.
  19. Inada Y., Wada T., Shibouta Y., Ojima M., Sanada T., Ohtsuki K., Itoh K., Kubo K., Kohara Y., Naka T., et al Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J. Pharmacol. Exp. Ther., 268: 1540-1547, 1994.[Abstract/Free Full Text]
  20. Aiyar N., Baker E., Vickery-Clark L., Ohlstein E. H., Gellai M., Fredrickson T. A., Brooks D. P., Weinstock J., Weidley E. F., Edwards R. M. Pharmacology of a potent long-acting imidazole-5-acrylic acid angiotensin AT1 receptor antagonist. Eur. J. Pharmacol., 283: 63-72, 1995.[Medline]
  21. Shibouta Y., Inada Y., Ojima M., Wada T., Noda M., Sanada T., Kubo K., Kohara Y., Naka T., Nishikawa K. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116). J. Pharmacol. Exp. Ther., 266: 114-120, 1993.[Abstract/Free Full Text]
  22. Sato K., Nishida N., Sasaki K., Chatani F., Sato S., Shikata M., Mitani M. Four-week oral toxicity study of TCV-116 in rats. Jpn. Pharmacol. Ther., 25: 11-28, 1996.
  23. Ishimura Y., Chatani F., Sato S. Four-week oral toxicity study of TCV-116 in 10-month-old beagle dogs. Jpn. Pharmacol. Ther., 24: 29-47, 1996.
  24. Nishida N., Sato K., Sato S., Ishimura Y., Chatani F., Mitani M. Twenty-six-week oral toxicity study of TCV-116 in rats. Jpn. Pharmacol. Ther., 24: 49-68, 1996.
  25. Nishikawa K., Naka T., Chatani F., Yoshimura Y. Candesartan cilexetil: a review of its preclinical pharmacology. J. Hum. Hypertens., 11 (Suppl.2): S9-S17, 1997.
  26. Weinberg M. S., Weinberg A. J., Cord R., Zuppe D. H. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. JRAAS, 2: S196-S198, 2001.



This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
M A Redondo-Muller, M Stevanovic-Walker, S Barker, J R Puddefoot, and G P Vinson
Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor
Endocr. Relat. Cancer, March 1, 2008; 15(1): 277 - 288.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Hunyady and K. J. Catt
Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II
Mol. Endocrinol., May 1, 2006; 20(5): 953 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Kosugi, A. Miyajima, E. Kikuchi, Y. Horiguchi, and M. Murai
Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer.
Clin. Cancer Res., May 1, 2006; 12(9): 2888 - 2893.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Uemura, H. Ishiguro, Y. Nagashima, T. Sasaki, N. Nakaigawa, H. Hasumi, S. Kato, and Y. Kubota
Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells
Mol. Cancer Ther., November 1, 2005; 4(11): 1699 - 1709.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Suganuma, K. Ino, K. Shibata, H. Kajiyama, T. Nagasaka, S. Mizutani, and F. Kikkawa
Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination
Clin. Cancer Res., April 1, 2005; 11(7): 2686 - 2694.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
N. Nagai, K. Noda, T. Urano, Y. Kubota, H. Shinoda, T. Koto, K. Shinoda, M. Inoue, T. Shiomi, E. Ikeda, et al.
Selective Suppression of Pathologic, but Not Physiologic, Retinal Neovascularization by Blocking the Angiotensin II Type 1 Receptor
Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 1078 - 1084.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miyajima, A.
Right arrow Articles by Hayakawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyajima, A.
Right arrow Articles by Hayakawa, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online